Colospan Announces FDA Approval of IDE for Intraluminal Bypass Device – an Alternative approach to Diverting Stoma

Colospan which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved the company’s investigational device exemption (IDE) application. With this IDE approval in hand, the company will launch its pivotal study for CG-100, a temporary Intraluminal Bypass Device, designed to reduce diverting stoma rates in patients undergoing gastrointestinal resection procedures.

Read More »

AMIT Invests $0.5M in Colospan

Colospan Ltd., a company developing revolutionary solutions for colorectal surgery, announced that AMIT (The Alfred Mann Institute at the Technion) has invested $0.5M in the company.

Read More »


J.P. Morgan 38th Annual Healthcare Conference (JPM 2020)

13-16 January 2020 | San Francisco, CA, USA

Emerging Medtech Summit 2020 - Colospan selected as Innovation leader

18-20 February 2020 | The Ritz-Carlton laguna niguel - Dana point, CA, USA

We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Privacy Policy. To agree to our use of cookies click Accept.